Prothena Corporation PLC. Daily Stock Analysis

Daily Stock Analysis, PRTA, Prothena Corporation PLC, priceseries

Prothena Corporation PLC. Daily Stock Analysis
Stock Information
Open
30.67
Close
30.27
High
31.06
Low
30.02
Previous Close
30.60
Daily Price Gain
-0.33
YTD High
49.77
YTD High Date
Jan 3, 2022
YTD Low
30.02
YTD Low Date
Mar 7, 2022
YTD Price Change
-18.95
YTD Gain
-38.50%
52 Week High
79.75
52 Week High Date
Sep 27, 2021
52 Week Low
20.08
52 Week Low Date
Mar 8, 2021
52 Week Price Change
9.65
52 Week Gain
46.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 3. 2017
55.55
Jul 27. 2017
63.73
17 Trading Days
14.73%
Link
LONG
May 10. 2018
14.79
May 17. 2018
15.69
5 Trading Days
6.11%
Link
LONG
Jan 4. 2019
10.89
Jan 22. 2019
11.64
11 Trading Days
6.91%
Link
LONG
Nov 11. 2019
9.14
Jan 3. 2020
14.98
36 Trading Days
63.88%
Link
LONG
Mar 23. 2020
9.14
Apr 3. 2020
10.37
9 Trading Days
13.45%
Link
LONG
Jun 29. 2020
10.27
Jul 23. 2020
12.47
17 Trading Days
21.37%
Link
LONG
Nov 3. 2020
11.36
Nov 9. 2020
11.95
4 Trading Days
5.22%
Link
LONG
Dec 4. 2020
11.53
Dec 9. 2020
12.22
3 Trading Days
5.96%
Link
LONG
May 21. 2021
24.42
Jun 22. 2021
45.36
21 Trading Days
85.73%
Link
LONG
Jul 8. 2021
55.22
Jul 12. 2021
58.32
2 Trading Days
5.61%
Link
LONG
Aug 2. 2021
52.74
Aug 16. 2021
56.73
10 Trading Days
7.56%
Link
LONG
Aug 19. 2021
59.11
Sep 24. 2021
75.44
25 Trading Days
27.62%
Link
Company Information
Stock Symbol
PRTA
Exchange
NasdaqGS
Company URL
http://www.prothena.com
Company Phone
011-353-1-236-2500
CEO
Gene G. Kinney
Headquarters
-
Business Address
ADELPHI PLAZA, UPPER GEORGE'S STREET, DUN LAOGHAIRE, CO. DUBLIN, IRELAND A96 T927
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001559053
About

Prothena Corp. Plc is a clinical stage biotechnology company, which engages in the discovery, development, and commercialization of novel antibodies. Its antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), inflammatory diseases including psoriasis, psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The company was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland.

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson's disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dun Laoghaire, Ireland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading